Difference between revisions of "Ependymoma"

Line 153:

**relatively unfavorable clinical outcome.

**CpG island methylator phenotype.<ref>{{Cite journal | last1 = Mack | first1 = SC. | last2 = Witt | first2 = H. | last3 = Piro | first3 = RM. | last4 = Gu | first4 = L. | last5 = Zuyderduyn | first5 = S. | last6 = Stütz | first6 = AM. | last7 = Wang | first7 = X. | last8 = Gallo | first8 = M. | last9 = Garzia | first9 = L. | title = Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. | journal = Nature | volume = 506 | issue = 7489 | pages = 445-50 | month = Feb | year = 2014 | doi = 10.1038/nature13108 | PMID = 24553142 }}</ref>

**Loss of H3K27me.<ref>{{Cite journal | last1 = Panwalkar | first1 = P. | last2 = Clark | first2 = J. | last3 = Ramaswamy | first3 = V. | last4 = Hawes | first4 = D. | last5 = Yang | first5 = F. | last6 = Dunham | first6 = C. | last7 = Yip | first7 = S. | last8 = Hukin | first8 = J. | last9 = Sun | first9 = Y. | title = Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. | journal = Acta Neuropathol | volume = | issue = | pages = | month = Jul | year = 2017 | doi = 10.1007/s00401-017-1752-4 | PMID = 28733933 }}</ref>

* Group B ependymomas:

**typically adults.

Difference between revisions of "Ependymoma"

Navigation menu

Search

@@ Line 153: / Line 153: @@
 **relatively unfavorable clinical outcome.
 **CpG island methylator phenotype.<ref>{{Cite journal  | last1 = Mack | first1 = SC. | last2 = Witt | first2 = H. | last3 = Piro | first3 = RM. | last4 = Gu | first4 = L. | last5 = Zuyderduyn | first5 = S. | last6 = Stütz | first6 = AM. | last7 = Wang | first7 = X. | last8 = Gallo | first8 = M. | last9 = Garzia | first9 = L. | title = Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. | journal = Nature | volume = 506 | issue = 7489 | pages = 445-50 | month = Feb | year = 2014 | doi = 10.1038/nature13108 | PMID = 24553142 }}</ref>
+**Loss of H3K27me.<ref>{{Cite journal  | last1 = Panwalkar | first1 = P. | last2 = Clark | first2 = J. | last3 = Ramaswamy | first3 = V. | last4 = Hawes | first4 = D. | last5 = Yang | first5 = F. | last6 = Dunham | first6 = C. | last7 = Yip | first7 = S. | last8 = Hukin | first8 = J. | last9 = Sun | first9 = Y. | title = Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. | journal = Acta Neuropathol | volume =  | issue =  | pages =  | month = Jul | year = 2017 | doi = 10.1007/s00401-017-1752-4 | PMID = 28733933 }}</ref>
 * Group B ependymomas:
 **typically adults.